To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as "orphan drugs").

referredUnited States· United States Congress· EN

Introduced

3 May 2022

Last action

—

Status

Referred to the House Committee on Energy and Commerce.

Summary

This bill reauthorizes through FY2027 the Food and Drug Administration's Orphan Products Grants Program, which supports clinical research and product development for rare diseases and conditions.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

3 official files

Introduced in House (text)

View file Download file

Introduced in House (text)
Introduced in House · EN · 3 May 2022
View Download Open at official source
Introduced in House (PDF)
Introduced in House · EN · 3 May 2022
View Download Open at official source
Introduced in House
summary · EN · 3 May 2022
Open at official source

Related records

No cross-record relationships stored yet.

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.

Official source: https://www.congress.gov/bill/117th-congress/house-bill/7640
Open data entity: https://api.congress.gov/v3/bill/117/hr/7640